• Citer

Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.

par Piccart-Gebhart, Martine ;Di Leo, Angelo ;Beauduin, Marc;Vindevoghel, Anita;Michel, Jeffrey;Focan, Christian;Tagnon, Alain;Ries, Fernand;Gobert, P;Finet, Claude;Closon-Dejardin, Marie Thérèse;Dufrane, J P;Kerger, Joseph ;Liebens, Fabienne ;Beauvois, Sylvie ;Bartholomeus, Sylvie;Dolci, Stella;Lobelle, Jean Pierre;Paesmans, Marianne ;Nogaret, Jean-Marie
Référence Journal of clinical oncology, 19, 12, page (3103-3110)
Publication Publié, 2001-06

Article révisé par les pairs

• Détails
• Contenu

Titre:	Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
Auteur:	Piccart-Gebhart, Martine; Di Leo, Angelo; Beauduin, Marc; Vindevoghel, Anita; Michel, Jeffrey; Focan, Christian; Tagnon, Alain; Ries, Fernand; Gobert, P; Finet, Claude; Closon-Dejardin, Marie Thérèse; Dufrane, J P; Kerger, Joseph; Liebens, Fabienne; Beauvois, Sylvie; Bartholomeus, Sylvie; Dolci, Stella; Lobelle, Jean Pierre; Paesmans, Marianne; Nogaret, Jean-Marie
Informations sur la publication:	Journal of clinical oncology, 19, 12, page (3103-3110)
Statut de publication:	Publié, 2001-06
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Antineoplastic Combined Chemotherapy Protocols -- adverse effects
	Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
	Belgium -- epidemiology
	Breast Neoplasms -- drug therapy
	Breast Neoplasms -- mortality
	Breast Neoplasms -- pathology
	Chemotherapy, Adjuvant -- methods
	Cyclophosphamide -- administration & dosage
	Disease-Free Survival
	Dose-Response Relationship, Drug
	Epirubicin -- administration & dosage
	Female
	Fluorouracil -- administration & dosage
	Humans
	Methotrexate -- administration & dosage
	Middle Aged
	Prognosis
	Proportional Hazards Models
	Statistics, Nonparametric
	Survival Rate
Note générale:	Clinical Trial
	Clinical Trial, Phase III
	Comparative Study
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:pmid/11408507